Aarti Drugs' record carries two distinct layers. The financial statements are audited, the GST dispute was fully set aside by the courts, and the auditor transition was routine. But the surrounding governance record is crowded: six years of SEBI and exchange compliance actions, a family succession that converts the retiring chairman into a paid consultant, and recurring related-party transactions that keep requiring shareholder approval.
Key findings
- Repeated SEBI and exchange actions for disclosure and insider-trading failures
Major- SEBI imposed a ₹1,00,000 penalty in June 2019 for promoter trading during a buyback window closure. A December 2023 warning covered failure to disclose a Gujarat Pollution Control Board plant closure order under Regulation 30, and a March 2025 warning went to the Compliance Officer for not covering all immediate relatives under the PIT Code. A non-executive director's contra trade of 500 shares led to disgorgement of ₹11,181 to SEBI's investor fund. - Family succession with a paid consultancy for the retiring chairman, and repeated public-institution dissent
Major- Chairman Prakash Patil retires September 30, 2026, and the Board approved his appointment as Management/Technical Consultant for five years at up to ₹2.5 crore per annum. His son Adhish Patil, CFO since 2014, was approved as Managing Director for five years from October 1, 2026. Director re-appointments drew 24-32% votes against from public institutions across the 2021 AGM and a 2022 postal ballot. - Related-party dealings concentrated in promoter-group purchases and subsidiary Pinnacle Life Science
Major- Standalone purchases from related parties rose to 58.31 crore in FY2021-22 from 43.17 crore. The company subscribed ₹25 crore to Pinnacle Life Science equity in January 2025 and approved a further ₹10 crore rights-issue investment in March 2026. Shareholders approved office-of-profit arrangements for promoter relatives, a brother and a daughter-in-law, each capped at ₹50 lakhs per annum. - A layered subsidiary group with off-book solar SPV stakes and one unaudited subsidiary in FY22-FY23
Major- The group added step-down entities Pharma Go SpA in November 2024 and Tripharma Chile SpA in February 2026 under Pinnacle Chile SpA. Pinnacle Life Science's paid-up capital reached ₹8.06 crore after two rights issues. Two 26.25% solar SPV stakes are classified as cost investments under Ind AS 109, with the company asserting no significant influence. One subsidiary's financials were unaudited and management-certified in both FY2021-22 and FY2022-23. - Cash conversion recovered, but capex, buybacks, and capitalisation choices support reported profit
Major- Cumulative CFO of ₹1,679 crore covered only 0.63x of cumulative EBITDA of ₹2,653 crore over ten years. CFO/PAT recovered from 0.34x in FY22 to 1.30x in FY26, while ROCE fell from 14.58% in FY24 to 11.52% in FY26. The company capitalised ₹9.03 crore of consolidated borrowing costs and ₹50.97 crore of R&D capex in FY26. Management disclosed an unquantified write-off of ageing capital WIP in Q1 FY27. - Revenue quality rests on insured receivables and export benefits; growth is price-driven
Minor- Trade receivables impairment was deemed unnecessary in FY2025-26 due to external credit insurance cover. Export benefits in sales fell to 3.85 crore in FY2022-23 from 11.84 crore in FY2021-22. Management reported Q1 FY27 volume growth of only \~3.5% against 19% revenue growth, with pricing up \~16-17% and acknowledged as war-driven and temporary. - Profits repeatedly shaped by tax-regime elections and one-off refunds
Minor- The company elected Section 115BAA and re-measured deferred tax in each year from FY2019-20 through FY2022-23. Management attributed Q1 FY27 PAT of ₹50.1 crore versus ₹54.0 crore to the prior year's ₹15 crore principal tax refund. The company itself stated EBITDA margins are "not exactly comparable YoY" due to Covid-era API margins. - The ₹230.70 crore GST notice was set aside; income tax disputes remain
Clean- A show cause notice proposed ₹230.70 crore IGST demand in August 2024, reduced to ₹20.72 crore in February 2025. The Bombay High Court granted relief in May 2025, and the Supreme Court dismissed the department's appeal on August 10, 2026. Disputed income tax demands of ₹92.38 crore remain pending as of March 31, 2024. - Statutory auditor rotated after a full term with no resignations or regulatory actions
Clean- Kirtane & Pandit served a full four-year term from August 2019 to the 38th AGM in September 2023. Gokhale & Sathe was appointed for five years at that AGM. CARO reports for FY2021-22 and FY2022-23 state no auditor resignation. Auditor fees rose steadily from ₹8.32 lakhs in FY2019-20 to ₹14.58 lakhs in FY2025-26.
What to watch
- 41st AGM, September 26, 2026. Votes on the Managing Director appointment, the consultancy for the retiring chairman, director re-appointments, and the new stock option plan.
- Chairman transition. Prakash Patil retires September 30, 2026; his consultancy begins October 1, 2026.
- CWIP write-off detail. Quantification and ageing of the Q1 FY27 write-off in subsequent disclosures.
- Related-party disclosures. Half-year disclosures due for the period ending September 30, 2026, including any further Pinnacle Life Science funding.
- Capex programme. Progress and funding of the ₹300-400 crore planned capex disclosed in the FY2025-26 annual report.
Bottom line: This is an audited, solvent record with a fully resolved GST dispute and a clean auditor transition. The risk is not in the numbers as filed, it is in the governance architecture around them: a family succession that pays the retiring patriarch, a dense web of promoter-linked transactions, and a compliance history that keeps drawing regulator attention. Read the related-party notes and the AGM agenda with that in mind, and watch whether the succession and the capex programme proceed as disclosed.